Dynavax Technologies Corporation (NASDAQ:DVAX) Q1 2024 Earnings Call Transcript

Donn Casale: Phil, it’s more around the operational hurdles, quite frankly, about just operationalizing a new vaccine and vaccine launches versus oncovin administration being the barrier for our retailers in particular.

Phil Nadeau: Got it. And in terms of hemodialysis, I think in the past, you’ve suggested that there is some use of HEPLISAV already in the market. Can you remind me if that’s true and if you have any estimates of penetration in the hemodialysis market currently?

Ryan Spencer: Yes. No, there’s definitely utilization in the marketplace. So yes, and you’re right. We have commented on that before. We have not commented on specific penetration or share other than our comments on retail and IDN. And like we have said before, until we have our PDUFA, our BLA approved, we’re going to refrain from getting into too many details on this segment.

Operator: Our next question will come from the line of Roy Buchanan with Citizens JMP.

Roy Buchanan: Just a quick follow-up on TdaP. I guess how many patients are you expecting in the extension trial? And it says in the press release versus active control. So are you going to be looking at both the TdaP-1018 and the Boostrix arms. It seems like a lot of patients have probably been off the trial for a while, maybe gone on to other things. Are you going to look at both the adults and the adolescent?

Rob Janssen: We’ll just be looking at — yes, we’ll just be looking at the young adults, Roy. We won’t be looking that much [indiscernible] too few. And the number of subjects we were looking to try to enroll was up to 50. We’ll be comparing TdaP-1018 to Boostrix.

Ryan Spencer: Yes. And Roy, just a couple of elements there. You already noted the trial was conducted a while with us. So we’ll have 2 to 3 years of follow-up on these patients. And the ultimate number is going to be depending on how many we can get to return given some of the challenging factors you noted, but we expect that we’ll be able to have some interesting data from the follow-up.

Operator: We have no further questions at this time. I would now like to turn the call over to Mr. Ryan Spencer, Chief Executive Officer, for closing remarks.

Ryan Spencer: Thank you, operator, and thank you all for joining us today. We appreciate your interest in Dynavax. We are excited about our recent accomplishments and the strength of our position. We look forward to updating you on our progress focused on protecting the world against infectious diseases. Operator, you may end the call.

Operator: Ladies and gentlemen, thank you for joining us today. This concludes today’s conference call. You may now disconnect. Everyone, have a wonderful day.